# Independent initial assessment: conditional pooled-response identification and discovery decisions

Assessment date: 2026-10-30. This assessment was written before reading proposer mechanism notes, reports, or coordinator interpretations. The dispatched frozen question was `review/question_v1.md`, identified in the assignment by SHA256 `abc0ddd54e18b99dedb1005aa27a4c185cdeffee6eb515e6736e38d40fdcea00`. I did not independently recompute that hash.

## Initial judgment

The equation and conditional identification argument are sound under the stated common-factor recovery model. The inspected original sources explicitly describe an endpoint based on pooled cell-count proportions. This makes a potentially useful distinction between relative response and a matched viable-burden fold. It does not establish that the dataset's authors intended an absolute endpoint, that the released data lack other calibration, or that an Agent improves discovery.

The immediate scientific gate is access to matched functional scale and recovery information, rather than a more elaborate predictor. Current source metadata permit a source/estimand audit and motivate a relative-response task; they do not yet establish the observations needed for an empirical absolute-threshold benefit test. The idea should remain conditional, with an actual data contract as the next gate. Ordinary algebra does not invalidate a useful scientific restriction, but the restriction and its practical consequences must be demonstrated separately from Agent value.

## Original source evidence

I inspected only the frozen question and the following supplied raw sources: publisher HTML `sources/root10_rhaister_article_redirect.body`, JATS `sources/root07_rhaister_explicit_redirect.body`, README `sources/root11_emerald_readme.body`, image receipt `sources/root12_rhaister_eq18.json`, and the local equation image `sources/rhaister_eq18.png`. HTML and JATS reproduce the same key methods passages; they are corroborating renderings of one article, not independent experiments.

1. **Observed equation.** JATS lines 84–86 locate `eqn18` and the original image reference `731197v1_eqn18.gif`; the rendered image visibly states

   `P[c,group] = n[c,group] / sum_c n[c,group]`

   `sensitivity[c,p] = log2(P[c,p] / P[c,control]).`

   The receipt records an HTTP-200 GIF response, complete body, and SHA256 `568eb43cd5d7e5680d09deecaca21d3174d1a2e1d8b6b99a1d1601a15e0e7db7`. I viewed the supplied PNG derivative; I did not independently regenerate it or hash the GIF. The identification question correctly transcribes the displayed equation.

2. **Culture, processing, and QC.** JATS paragraph `p-83` (line 83), also HTML `p-83` (line 441), says exactly:

   > Cells were harvested 5 days after drug or DMSO treatments, yielding 1,831,648 cells passing full QC filters and an extra 291,765 passing minimal QC filters. Bioinformatics processing was similar to Tahoe-100M, with fastq files first processed using split-pipe followed by genotype-based cell line demultiplexing based on Demuxlet. Cell counts used for sensitivity quantification uses the minimal QC filters, while gene expression data used for additional predictors of sensitivity uses full QC filters.

   These are acquired/QC-passing cell totals, not an asserted per-culture absolute viable-count assay. The distinction between minimal and full QC matters for any attempt to reconstruct sensitivity from released transcriptomic rows.

3. **Stated biological motivation.** JATS/HTML `p-27` says:

   > Defining drug sensitivity by relative growth rate inhibition (relative decrease in cell count compared to vehicle) is frequently used as the primary phenotype. Context-specific drug sensitivity is of particular interest, since selectivity for certain cancer subtypes based on shared genetics or transcriptional states is used as a proxy for selectivity for those cancers.

   This is motivation, not an additional mathematical calibration. The methods equation determines the documented endpoint. A terminology mismatch would warrant clarification, not a conclusion of author error.

4. **README explicitly describes composition.** README lines 34–35 state:

   > The dataset provides two readouts: a transcriptional profile at single-cell resolution and a drug-phenotype measure derived from cell-count proportions at the five-day endpoint.

   README lines 101–105 describe `DMSO_TF` as vehicle controls, a compound/concentration key, cell-line identity, and `sample` as a “Unique sample identifier (distinguishes replicate treatments).” This establishes advertised keys, not verified replicate counts or matching across assay modalities.

5. **Advertised summary structure.** README lines 178–181 state:

   > Per-(cell line, condition) growth-rate summary statistics: 4,992 rows covering 52 cancer cell lines × 93 conditions (single-drug, drug-combination, and `DMSO_T0` time-zero controls). This is the raw summary table; downstream loaders typically drop `DMSO_T0`, exclude multi-drug conditions, and mean-aggregate replicates per (cell line, condition).

   Lines 185–187 advertise only `cell_line`, `condition`, and `growth_rate`, with the last described as “Scalar growth-rate response of the cell line to the treatment.” That label alone does not establish a time-zero-normalized growth-rate calculation. The row count and coverage description are not a complete rectangular, replicate-resolved data contract; their exact meaning requires metadata verification. I did not read any summary-table response values.

The inspected methods do not supply a viable-total calibration or detailed recovery validation. This is a limit of the inspected evidence, not proof those observations never existed. README instructions, advertised tutorials, and article references were not followed or executed.

## What the algebra identifies

Let `0` denote matched endpoint vehicle, let positive true viable burdens be `N[c,p]` and `N[c,0]`, and suppose recovered counts satisfy `n[c,p] = s[p] N[c,p]`, with one scalar sampling factor per sample and the same cell-line universe in both denominators. Write `R[c,p] = 2^sensitivity[c,p]`, `g[c,p] = N[c,p]/N[c,0]`, and `G[p] = sum_c N[c,p]/sum_c N[c,0]`. Direct substitution gives `R[c,p] = g[c,p]/G[p]`.

Thus `g = G R` is a conditional identity. For a fixed relative composition and any positive scalar multiplier of the entire treated burden vector, the relative observation remains unchanged. Baseline proportions impose the compositional constraint `sum_c P[c,0] R[c,p] = 1`; they do not recover the lost scale.

Supported under this model:

- Within one drug/dose/pool, `R[c,p]/R[d,p] = g[c,p]/g[d,p]`. Ranking lines by their *treated/control folds* and asking which line is more inhibited relative to another remain identified. This is a comparison of relative folds, not absolute surviving cell numbers or clinical therapeutic index.
- Ratios of those pairwise ratios across conditions also cancel each condition's scale, if cell identities and comparable baselines are defined. Relative selectivity changes can therefore be meaningful without `G`.
- A measured matched `G` recovers each line's viable-burden fold under the common-factor model. One condition-level measurement informs all the lines in that same pool; query costs must reflect this sharing.
- A validated interval `[L,U]` for `G` gives an interval `[L R, U R]` for a positive fold. A threshold decision is identified if the entire interval lies on one side of the threshold. Estimated bounds must retain their uncertainty.

Not supported from relative observations alone:

- An unqualified threshold such as “this line retains at most 20% of matched vehicle burden.”
- A fixed line's absolute fold ranking across drugs with distinct unknown `G` values. It can become identified with common scales or sufficiently restrictive bounds; saying such rankings are *always* impossible would be too broad.
- Death versus slowed division, net expansion versus time zero, an absolute cell number, a growth rate per unit time, or a normalized GR metric. A vehicle-relative endpoint fold still needs baseline counts/time information for those other estimands.
- A universal drug property independent of the pool. Co-culture can change competition, paracrine effects, nutrient use, and effective exposure. The identity concerns this culture system; transport to monoculture, organoids, normal tissue, or patients needs further evidence.

An analytic counterexample to interpreting zero relative effect as no functional effect is uniform suppression: if every line's endpoint burden is multiplied by the same factor, all `R` values equal one. Uniform net expansion would also leave them equal to one. These are hypothetical constructions, not empirical findings about Emerald Bay. Conversely, enrichment in the treated pool can coexist with a lower burden than vehicle, because the rest of the pool may decline more.

## Recovery assumptions and edge cases

The most consequential distinction is between common sampling, stable line-dependent recovery, and treatment-dependent recovery.

**Stable line-dependent recovery.** Suppose `n[c,p] = s[p] a[c] N[c,p]` with unknown positive `a[c]`. Then

`R[c,p] = g[c,p] / G_a[p]`, where `G_a[p] = sum_c a[c] N[c,p] / sum_c a[c] N[c,0]`.

Within-drug ratios of folds remain identified because `G_a` is common. A physical unweighted viable-total fold `G` does **not**, by itself, justify the simple correction `g = G R`. A small analytic counterexample is baseline burdens `(1,1)`, stable recovery weights `(1,2)`, and treated burdens `(1,1/2)`. The observed relative ratios are `(3/2,3/4)` and the physical total fold is `3/4`; multiplying them does not return the true folds `(1,1/2)`. Therefore stable recovery is enough for pairwise selectivity, but not enough for the proposed unweighted-total correction.

This objection has resolutions that should not be overlooked: calibrated recovery weights can reconstruct composition, or independently known *true* baseline fractions `w[c] = N[c,0]/sum N[c,0]` allow `g[c,p] = G[p] R[c,p] / sum_c w[c] R[c,p]` under stable weights. A validated absolute fold for an internal reference line can also identify the common scale. Merely calling a line “insensitive” is not that validation, and recovered baseline proportions are not automatically true baseline fractions.

**Treatment-dependent recovery.** If recovery changes differently by line and treatment, even pairwise fold ratios can fail. For example, equal true folds combined with a twofold increase in the recovery of one line produce an apparent differential response. Drugs can alter dissociation, adherence, cell size, fragility, RNA content, assignment quality, or eligibility for QC. A matched physical total alone cannot separate such distortions. Minimal QC is relevant but does not establish unbiased viable-cell capture.

Additional conditions that matter in a test:

- A viable-total assay and the sequencing statistic must refer to the same culture, time, cell universe, and viable population. ATP, fluorescence, raw captured cells, live nuclei, and viable cells are different quantities until validated. Excluding dead cells or unassigned cells can introduce a changing denominator.
- Vehicle matching, plate/batch, seeding composition, dose, duration, pooling and sample identity must be explicit. Averaging drug/vehicle ratios or logs across replicates generally does not commute with applying one aggregate total correction.
- At finite sampling, the proportionality is an observation model for probabilities or expected counts, not an exact relation between every observed count and true burden. Ratios and logarithms require uncertainty treatment, especially for rare lines.
- A positive baseline for the line is required for a finite fold. A zero recovered treatment count does not prove zero viable burden. Pseudocounts change the exact identity; total pool extinction leaves the composition undefined.
- If omitted or unclassified populations contribute to a physical total but not the composition denominator, `G` must be reconciled to the measured population.
- `DMSO_T0` proportions add an initial composition, not its total scale. Paired absolute time-zero counts could support additional questions, but their existence and measurement compatibility are not established here.

## Drug-discovery usefulness and the Agent claim

A defensible useful task is advancing candidate drug/dose conditions for specified cancer contexts only when a matched five-day viable-burden fold meets an explicit efficacy threshold, while reporting uncertainty and pool scope. A second, already supported task is finding relative selectivity across cell contexts. These tasks should have separate labels and evaluation criteria. Selecting among cancer lines alone does not establish safety in healthy tissue; combination rows alone do not establish synergy without an appropriate reference model and dose design.

A virtual-cell component could predict functional fold and the assay mapping jointly, or produce a constrained set of possible outcomes that depends on unresolved scale. That is a legitimate functional prediction target. It does not yet require a detailed cellular simulator, and the source audit supplies neither a validated simulator nor evidence that transcription predicts the missing scale.

The strongest simple explanation of an apparent benefit is measurement correction plus ordinary decision theory. Strong rivals include:

1. Deterministic correction with exactly the same measured scale and recovery information.
2. Recording a cheap total for every condition at harvest, followed by fixed correction and thresholding.
3. The same ordinary response predictor trained on corrected labels, with uncertainty-aware thresholding.
4. A fixed or simple uncertainty-based query/abstention rule using the same bounds and costs.
5. A directly population-resolved functional assay, when its cost and biological setting are comparable.

An Agent could add a measurable capability by selecting which additional observation resolves an actual decision, updating its outcome inference, and stopping or abstaining with calibrated confidence. Calling this an Agent does not demonstrate an advantage over an ordinary sequential policy. The incremental contribution requires better decision outcomes or lower total cost at matched error/coverage than the strongest policies with the same information and actions.

If every positive `G` is admissible and the threshold is finite and positive, every nonzero observed response can cross that threshold as `G` changes. An adaptive policy cannot claim selective savings merely from inspecting such relative values. Defensible bounds, transferable scale predictions with validated uncertainty, informative alternative observations, or a mixed relative/absolute task are needed. Retrospectively querying an endpoint may also be physically infeasible after the culture has been harvested: a re-run or prospectively reserved sample can cost a new biological interval. Fixed total recording may dominate adaptivity when marginal collection cost is low.

Count initialization, historical labeled observations, recovery calibration, repeats, assay preparation, human/operator work, compute, and biological elapsed time equally. A hidden total available only to a benchmark oracle is useful for an authorized retrospective replay, but is not a cheap accessible acquisition action unless its real production route is documented.

## Actual data contract before an effect or benefit test

The README supports public accessibility in principle and compact response metadata. It does not yet verify the following contract:

| Needed observation or specification | Why it can change feasibility |
| --- | --- |
| Exact definition and transformation of `growth_rate`, including control aggregation and pseudocounts | The released column must actually equal the quantity being analyzed; a name or Eq18 citation is insufficient to verify all loader transformations. |
| Replicate-resolved sample/plate/pool/dose/time keys and matching controls | Required to pair folds, totals and uncertainty without incompatible aggregation. |
| Minimal-QC per-line counts or a justified equivalent, and denominator membership | Full-QC expression rows are not automatically the sensitivity population. |
| Matched absolute viable-total measurements for drug and endpoint vehicle, with units and assay protocol | Required to anchor `G` under the common-factor model. Existence must be established before promising an empirical absolute effect test. |
| Recovery validation, known weights, or independently measured true composition/reference folds | Determines whether a total measurement identifies per-line folds or only a biased reconstruction. |
| Independent population-resolved functional measurements on a suitable subset | Can test the recovery model and reconstruction; using `G R` as both inferred result and sole ground truth only verifies the identity. |
| A feasible acquisition menu with per-condition shared costs, timing and repeat costs | Needed to compare selective measurement to fixed collection without fictitious cheap queries. |
| Prespecified threshold, eligible contexts, coverage/error tradeoff, held-out units and baseline policies | Prevents redefining the discovery task around a favorable result. Drug/dose relatives and co-cultured lines must not create leakage across claimed generalization units. |

This is a staged gate, not a demand to acquire every assay before any useful work. Metadata-only feasibility checks can establish schemas, matching and availability first. Verified relative labels can support a relative prediction test. Matched totals with a defensible recovery model can support a conditional reconstruction test. Independent functional validation and a realistic acquisition ledger are needed for a persuasive discovery-decision/Agent benefit test.

Cross-database responses or a monoculture assay should not automatically be substituted as the missing matched pool scale: exposure, time, cell state, and interactions can differ. A purely synthetic scale construction can illustrate nonidentification or evaluate behavior under declared assumptions, but cannot show how often the problem changes real drug advancement decisions. If suitable matched observations are unavailable at low cost, that is a reason to narrow the empirical claim to a relative endpoint or select a different accessible dataset, rather than infer an unobserved absolute outcome.

## Objections to resolve and exposure limits

The key unresolved objections are: whether the released labels equal Eq18 after all processing; whether compatible absolute/recovery observations exist; whether any important decisions actually change under validated scale information; and whether a sequential Agent adds value beyond fixed collection and simple correction/policies. None is resolved by the frozen question alone. The useful contribution could be a rigorously restricted measurement-aware discovery workflow, but novelty and practical advantage remain untested.

I made zero network/API tool calls, zero scientific tests, and zero raw numeric-response accesses. I did not open summary-table `growth_rate` values/statistics, protected `.env` files, PRISM24Q2, CTRP, sealed or confirmation material, proposer notes, or coordinator reports. I did not install packages, execute author code, or create subagents. The permitted Python interpreter was used only to inspect supplied source text and source locators; analytical counterexamples above were reasoned examples, not fitted or simulated outcomes. The original article's published narrative performance numbers appeared incidentally during source text searches; they were not used as evidence for this question's empirical benefit.

The assignment requested Sol/high. The actual serving model identity, effective reasoning setting, token accounting, and monetary cost were not exposed to me as verifiable runtime metadata, so I cannot attest to them. This review has no authority to limit the overall research effort; it identifies the evidence gates for this particular conditional question.

## Dated amendment — 2026-10-30: acquired identity/schema metadata

This amendment follows preservation of the initial assessment. I read `data/summary_metadata.json` and the text of `data/inspect_summary_metadata.py`; I did not execute the script or open the response table. The script explicitly projects only `cell_line` and `condition` through `parquet.read(columns=['cell_line', 'condition'])`, reads schema/row metadata, and hashes the source bytes. Physical acquisition and hashing of a response-containing file must be distinguished from semantic access to its numeric response column. The metadata artifact reports the file SHA256 as `3b4b9e451eab1106b7e47aac1b68d5181f0e684c021c88fc63f0dca01d7cc5c9`. The coordinator reports agreement with the HF LFS object identifier; I did not independently inspect the HF receipt or establish that comparison.

The metadata now resolves the earlier row-count uncertainty: 4,992 rows cover all 4,836 distinct keys from 52 lines and 93 condition strings. There are 4,784 keys with one row and 52 keys with four rows; only endpoint vehicle `DMSO_TF` has four rows per line. `DMSO_T0` has one row per line. This supports complete identity-level coverage of the advertised condition grid. It does **not** establish four independent biological vehicle preparations: the table has only `cell_line`, `condition`, and `growth_rate`, with no sample, plate, batch, replicate, or preparation identifier. Each noncontrol key has a single released row, which does not tell us whether that row aggregates upstream preparations. Vehicle row order cannot safely supply drug-control matching. The README's general language about mean-aggregating replicates must therefore remain qualified to observed row multiplicity and separately documented upstream design.

There are 44 noncontrol single-drug condition strings spanning 19 drug names, 47 combination condition strings, and the two controls. Dropping time zero while retaining endpoint vehicle gives 45 single-tuple conditions. This offers a plausible numerical reconciliation with article paragraph `p-84`'s “45 singled-rug perturbations” and 19 unique drugs, **if** that convention counts endpoint vehicle in the 45 but excludes it from the drug count. Metadata arithmetic alone does not establish the original filtering convention, doses, or split membership.

Article paragraph `p-85` separately describes six panel drugs and 14 non-panel drugs, which would imply 20 distinct drug labels if those sets are disjoint as written. That is not fully reconciled with 19 noncontrol single-drug names. Inclusion of vehicle as a perturbation label is one possible explanation, alongside differing filtering/naming or a textual counting discrepancy. No explanation is established here. Obtain the actual split manifest and treatment/control convention before asserting an author error, reproducing the claimed split, or silently changing it to six plus thirteen. A source ambiguity should be recorded as such rather than used as evidence about response biology.

Admission is **unchanged for an absolute-threshold/Agent-benefit test**: this compact table supplies neither matched physical totals nor recovery validation, sample pairing, or independent functional ground truth. The new evidence strengthens admission for a cheap identity/schema audit and establishes the intended relative-label matrix's coverage; numeric label definition and validity remain unverified. It also narrows the replication claim: four endpoint-vehicle rows per line are observed, while independent preparations and response-level variability remain unknown. No response values or statistics, scientific tests, network/API calls, or author code execution were added by this amendment. The initial text above remains unchanged, and the frozen question was not edited.
